Loading clinical trials...
Loading clinical trials...
A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer.
The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Research Site
Birmingham, Alabama, United States
Research Site
Mobile, Alabama, United States
Research Site
Scottsdale, Arizona, United States
Research Site
Tucson, Arizona, United States
Research Site
Berkeley, California, United States
Research Site
Laguna Woods, California, United States
Research Site
Newport Beach, California, United States
Research Site
San Diego, California, United States
Research Site
San Francisco, California, United States
Research Site
Santa Monica, California, United States
Start Date
August 1, 1995
Primary Completion Date
July 1, 2008
Completion Date
August 1, 2008
Last Updated
June 6, 2012
3,618
ACTUAL participants
Bicalutamide
DRUG
Placebo
DRUG
Lead Sponsor
AstraZeneca
NCT04400656
NCT06204302
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions